Guthán: 01 8647100



Primary Care Reimbursement Service Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3

Tel: 01-8647100

Johnny Mythen, T.D. Dáil Éireann, Leinster House, Kildare Street, Dublin 2.

26th April, 2021

PQ: 20314/21

To ask the Minister for Health if he plans to add drugs for treatment for hyperemesis gravidarum to the drugs payment scheme; the approved drugs list for hyperemesis gravidarum under the drugs payment scheme; the treatments available under the drugs payment scheme to treat hyperemesis gravidarum; and if he will make a statement on the matter. -Johnny Mythen

Dear Deputy Mythen,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 20314/21), which you submitted to the Minister for Health for response.

Cariban (doxylamine / pyridoxine) is an unlicensed product that is not reimbursable under GMS and Community Drug Schemes. Only licensed products are added to the formal GMS Reimbursement List in line with the Health (Pricing and Supply of Medical Goods) Act 2013.

Xonvea® (doxylamine / pyridoxine) is the licensed product with the Health Products Regulatory Authority (HPRA) in Ireland. Xonvea is currently undergoing formal pricing and reimbursement assessment http://www.ncpe.ie/drugs/doxylamine-pyridoxine-xonvea/. To date, a pricing and reimbursement application has not been received by the HSE for Navalem®(doxylamine / pyridoxine) which is also licensed by the HPRA in Ireland.

Under the legislation there are formal processes which govern applications for the pricing and reimbursement of medicines. The HSE does not reimburse medicines or agree reimbursement terms in advance of the completion of the required processes. The HSE does not intend to reimburse Cariban under Community Drug Schemes or review the clinical evidence for this unlicensed product. As there is a licensed product (Xonvea®) available in Ireland going through the formal process, the clinical evidence for this product will be examined as part of the national pricing and reimbursement assessment. Yours sincerely,

Suzanne Doyle

Primary Care Eligibility & Reimbursement Service